Corbus Pharmaceuticals Holdings, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $3.60 million for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-09.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2020-11-09
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2020-09-30 was -$32.67M.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2020-06-30 was $17.80M.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2020-03-31 was $18.48M.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2017-03-31 was $3.50M.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2016 was $2.56M, a 98.52% increase from fiscal 2015.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2015 was $1.29M, a 25.49% decline from fiscal 2014.
- Corbus Pharmaceuticals Holdings, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2014 was $1.73M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2020-09-30 | -$32.67M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-09 | -$14.87M derived: sum of 2 quarters · filed 2020-11-09 | $3.60M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $17.80M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-31 | $36.27M 10-Q/A · filed 2020-08-31 | ||
| 2020-03-31 | $18.48M 10-Q · filed 2020-05-11 | |||
| 2019-09-30 | $21.11M 10-Q · filed 2019-11-07 | |||
| 2018-09-30 | $12.36M 10-Q · filed 2019-11-07 | |||
| 2017-03-31 | $3.50M 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | $2.56M 10-K · filed 2017-03-08 | |||
| 2015-12-31 | $1.29M 10-K · filed 2016-03-28 | |||
| 2015-03-31 | $1.95M 10-Q · filed 2015-05-13 | $3.37M derived: sum of 2 quarters · filed 2015-05-13 | ||
| 2014-12-31 | $1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-10 | $1.73M 10-K · filed 2015-02-10 | ||
| 2014-09-30 | $307.03K 10-Q · filed 2014-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |